Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IOVA News 3 November 2025 - 23 December 2025

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back on traders’ radar heading into Dec. 23, 2025, after a sharp move higher to $2.78 at the Dec. 22 close (up 12.10% on the day) and an early pre-market indication around $2.80. StockAnalysis That bounce matters because Iovance has become the kind of stock where small news can hit like a cymbal crash—and not just because it’s biotech. With short interest around one-third of the float (by recent exchange reporting), any new analyst note, operational update, or sentiment shift can amplify price swings. MarketBeat Below is a detailed roundup of the current news,
23 December 2025
···
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

December 18, 2025 — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to reignite the “is this finally a bottom?” debate around one of biotech’s most volatile commercial launches. According to Investing.com’s recent trading history, IOVA jumped 12% on Wednesday, December 17, closing at $2.52 on 23.27 million shares after already rising on December 16. Investing.com As of December 18, the stock continued to trade around $2.52, with a recent 52-week range of
18 December 2025
·····
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel (brand name Amtagvi) earned FDA approval in 2024 as the first-ever TIL therapy (and the first cellular therapy for any solid tumor)cancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapies (e.g.
3 November 2025
···

Stock Market Today

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

7 February 2026
Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
BitMine Immersion (BMNR) stock whipsaws with ether — what to watch before Monday

BitMine Immersion (BMNR) stock whipsaws with ether — what to watch before Monday

7 February 2026
BitMine Immersion Technologies shares rose 16.8% to $20.32 Friday after a 14.3% drop Thursday, tracking sharp swings in ether and bitcoin. Trading volume hit 54 million shares. The company held over 4.2 million ether and 193 bitcoin as of Feb. 1, with nearly 2.9 million ether staked, according to an SEC filing. Crypto price moves over the weekend are expected to drive Monday’s open.
Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Go toTop